GlassScriptPhysician profile
Megan Moore
NPI 1811518830
$1,985.47
in general payments reported to CMS, 2019-2025
22 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $206 · 2023: $189 · 2024: $391 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.71 |
| Education | $133.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $297.37 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $247.92 | 2021-2025 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $200.54 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Harmony Biosciences LLC | $192.24 | 2025 | |
| Philips North America LLC | $167.58 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.34 | 2021-2025 | Jascayd, Ofev |
| Insmed, INC. | $103.59 | 2023-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $92.22 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $84.32 | 2025 | Dupixent |
| Chiesi USA, INC. | $76.36 | 2021 | |
| Pfizer INC. | $75.96 | 2021 | |
| Amgen INC. | $55.73 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $41.92 | 2025 | Tyvaso |
| Mylan Specialty L.P. | $37.91 | 2022-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $34.76 | 2023 | Nuzyra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.19 | 2024 | Glassia |
| Grifols USA, LLC | $21.60 | 2025 | Prolastin-C Liquid |
| Melinta Therapeutics, LLC | $19.33 | 2023 | Rezzayo, Vabomere |
| Viatris Specialty LLC | $15.42 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $14.68 | 2025 | |
| Gilead Sciences, INC. | $14.24 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.